Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank71
3Y CAGR+0.5%
5Y CAGR+14.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+0.5%/yr
vs +64.7%/yr prior
5Y CAGR
+14.4%/yr
Recent deceleration
Acceleration
-64.2pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $94.30M | -20.1% |
| 2024 | $118.00M | +14.1% |
| 2023 | $103.39M | +11.3% |
| 2022 | $92.89M | +7.0% |
| 2021 | $86.78M | +80.1% |
| 2020 | $48.18M | +98.4% |
| 2019 | $24.28M | +92.4% |
| 2018 | $12.62M | - |